Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Autor:
Liqun Huang, Nengtai Ouyang, Basil Rigas, Gang Xie, Ka-Wing Cheng, Timothy S. Wiedmann, Ninche Alston, Gerardo G. Mackenzie, Chi Chun Wong
Publikováno v:
Molecular Cancer Therapeutics. 12:1417-1428
Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome
Publikováno v:
Cancer Research. 72:P4-07
The PI3K/Akt/mTOR pathway is involved in breast cancer resistance to endocrine therapy. Inhibitors of mTOR have been shown to have benefit for patients with ER positive tumors that have developed endocrine therapy resistance. Inhibition of mTOR trigg
Autor:
Nan Liu, Yin Sun, Chaozhao Liang, Ryan K. Thor, Elaine Hsia, Robert Damoiseaux, Boxiao Ding, Sheng Tai, Sunita Bhuta, Jiaoti Huang
Publikováno v:
Molecular Cancer Therapeutics. 11:1320-1331
PI3K/AKT/mTOR pathway plays a key role in the tumorigenesis of many human cancers including prostate cancer. However, inhibitors of this pathway, such as Rad001, have not shown therapeutic efficacy as a single agent. Through a high-throughput screen
Autor:
Mark Ferrer, Ira Pastan, Antonella Antignani, Nathan Simon, Evan Angelus, Manjie Huang, Lesley Mathews-Griner, David J. FitzGerald, Craig J. Thomas
Publikováno v:
Molecular Cancer Research. 14:A67-A67
Pseudomonas exotoxin (PE)-based immunotoxins (antibody-toxin fusion proteins) have produced frequent complete remissions in patients with hairy cell leukemia but far fewer responses in other cancers. PE and PE-immunotoxins kill cells via a pathway th
Autor:
Sandeep Gupta, Vaibhav Sihorkar, Sanjeeva Reddy, Mahaboobi Jaleel, Vijay Kumar Nyavanandi, Niranjan Rao, Murali Ramachandra, Hosahalli Subramanya, Roger Smith, Scott K. Thompson, Aravind Basavaraju
Publikováno v:
Molecular Cancer Therapeutics. 14:B100-B100
Various genes in RAS-RAF and PI3K pathways are frequently mutated in a wide variety of solid tumors. Concurrent double mutations are also observed quite often in a broad range of tumor types. Combined inhibition of both pathways has been shown to imp
Autor:
Shingo Dan, Yumiko Nishimura, Naomi Tamaki, Takao Yamori, Sho Isoyama, Naoki Nakamura, Mutsumi Okamura, Gensei Kajiwara
Publikováno v:
Cancer Research. 73:4450-4450
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers. Therefore PI3K is thought to be a promising target for cancer therapy, and many compounds targeting PI3K have been developed and tested in clinical trials. Acq
Publikováno v:
Cancer Research. 73:2063-2063
The K-RAS mutation, resulting in activation of the Raf/MEK/ERK pathway, has been implicated in pancreatic cancer development. And the PI3K/Akt pathway is highly activated in pancreatic cancer and considered to be a cancer hallmark. The principal obje
Publikováno v:
Clinical Cancer Research. 18:B25-B25
Introduction: The purpose of this study is to investigate the effects of two PI3K pathway inhibitors on a panel of NSCLC cell lines, with a view to developing resistant cell line models, through exposure to the inhibitors over an extended period of t
Autor:
Carter Fields, Gail Lewis Phillips, Gabriele Schaefer, Lily Shao, Lisa Crocker, Mark X. Sliwkowski
Publikováno v:
Cancer Research. 72:1212-1212
Dysregulation of the epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) by mutation and/or overexpression plays an important role in tumorigenesis, and targeted agents directed against two members of the HER/ErbB family, epidermal growt
Autor:
Katti Jessen, Mathew Janes, Jeff Kucharski, Katrina Chan, Lian-Sheng Li, Levan Darjania, Christian Rommel, Shunyou Wang, Yi Liu, Urmi Banerjee, Lucy Lan, Josh Stewart, Xin Xin Guo, Marikka Elia, Linda Kessler, Pingda Ren, Michael C. Martin, Jocelyn Staunton
Publikováno v:
Cancer Research. 72:3753-3753
Background: Multiple agents that inhibit angiogenesis and tumor cell growth via the VEGF and mTOR (TORC1) pathways have been approved for locally advanced or metastatic renal cell carcinoma (RCC) in recent years. Despite this progress, improving over